title: [Is "COMET" pointing in the right direction?--Con].
authors.affiliation: Klinik III für Innere Medizin, Universität zu Cologne. christian.schneider@medizin.uni-koeln.de
authors.forename: C A
authors.initials: CA
authors.lastname: Schneider
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000401:mortality; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008790:Metoprolol / Q000009:adverse effects / Q000627:therapeutic use*; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol